Dialysis News: Breaking Dialysis News, Comments and Articles. - Page: 2

TVA Medical Raises $9.5 Million to Advance Minimally Invasive Therapy for End-Stage Renal Disease

AUSTIN, Texas, June 10, 2013 /PRNewswire/ -- TVA Medical, Inc. (TVA Medical), a medical device company developing minimally invasive therapies for End-Stage Renal Disease (ESRD), announced today that it received $9.5 MM in Series B financing.  S3 Ventures led the round and was joined by TriStar Technology Ventures and existing investor, Santé Ventures.  The funding will be used...

Medicare ESRD Payment Should Account For Epogen Price Increase, Dialysis Centers Say

Dialysis centers write to CMS saying that upcoming Medicare payment cuts for end-stage renal disease treatment, combined with a 5% Epogen price increase, will put “additional pressure on already thin Medicare margins.”

CryoLife Receives CE Mark For HeRo® Graft

ATLANTA, June 10, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today achievement of a CE (Conformite Europeenne) Mark for the HeRO (Hemodialysis Reliable Outflow) Graft system produced at the Company's new manufacturing facility in Atlanta. The HeRO Graft is a proprietary graft-based solut...

Whitehead Institute researchers identify drug target for anemia

Researchers at Whitehead Institute have identified a protein that is the target of glucocorticoids, the drugs that are used to increase red blood cell production in patients with certain types of anemia, including those resulting from trauma, sepsis,...

Dialysis patients, doctors often out of sync on prognosis

Scientists identify potential drug target for treatment-resistant anemias

Researchers at Whitehead Institute have identified a protein that is the target of glucocorticoids, the drugs that are used to increase red blood cell production in patients with certain types of anemia, including those resulting from trauma, sepsis,...

Cantel Medical April 2013 Quarter Results And Outlook

By William Meyers: Cantel Medical (CMN) is a leader in several specialties within the infection control for healthcare market. It recently acquired SPS in the healthcare disposables segment, adding to a list of successful acquisitions over the last few years. The other segments are: endoscopy sterilization and disposables; water purification; and therapeutic filtration (mainly for dialysis). In Ma...

Bioengineered Blood Vessels Successfully Implanted In Patient

Brett Smith for redOrbit.com - Your Universe Online Surgeons at Duke University have announced the successful implantation of a bioengineered blood vessel in the United States. “This is a pioneering event in medicine,” said Dr. Jeffrey H. Lawson, a vascular surgeon and vascular biologist at Duke Medicine who helped develop the technology. “It’s exciting to see something you’ve worke...

Bioengineered Vein Implanted Into Kidney Dialysis Patient

In a first-of-its-kind operation in the United States, a team of doctors at Duke University Hospital helped create a bioengineered blood vessel and transplanted it into the arm of a patient with end-stage kidney disease. The procedure, the first U....

Circulation 62% More Likely to Return with ZOLL AutoPulse

Clinical Benefits Unmatched by Other Mechanical CPR Systems ZOLL® Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that a paper just published in Critical Care Medicine reported the likelihood of achieving a return of spontaneous circulation (ROSC) after sudden cardiac arrest (SCA) is 62% gr...

Mitsubishi Pharma Europe selects NextPharma for European launch of BindRen®

NextPharma Technologies Holding Ltd announced today that Mitsubishi Pharma Europe (MPE), the European subsidiary of Mitsubishi Tanabe Pharma Corporation, has selected NextPharma as its fully-serviced outsourcing partner for the European launch of BindRen®. NextPharma will provide tailored, primary and secondary packaging solutions within the European terr...

Surgeons implant bioengineered vein: Kidney dialysis patient first in U.S. to receive lab-grown blood vessel

In a first-of-its-kind operation in the United States, a team of doctors created a bioengineered blood vessel and implanted it into the arm of a patient with end-stage kidney disease. The procedure, the first U.S. clinical trial to test the safety an...

Cantel Medical Reports EPS of $0.33 vs. $0.30 on 8% Sales Increase for Third Quarter Ended April 30, 2013

LITTLE FALLS, N.J., June 6, 2013 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE: CMN) reported a 10% increase in net income to $8,998,000, or $0.33 per diluted share, on an 8% increase in sales to $105,009,000 for the third quarter ended April 30, 2013. This compares with net income of $8,174,000, or $0.30 per diluted share, on sales of $97,238,000 for the third quarter ended April 30, 2012. For the n...

Use of Phosphate Binder 'Sensipar' Declines in Dialysis Clinics

EXTON, Pa.—BioTrends Research Group, a research and advisory firm for specialized biopharmaceutical issues, finds that the use of phosphate binders in the United States has declined in the hemodialysis and peritoneal dialysis setting over the past two years.

Why Do Dialysis Patients Have Increased Risk of Heart Attack?

BETHESDA, Md.—Patients with advanced kidney disease who are undergoing hemodialysis are known to be highly susceptible to heart attacks and other cardiovascular complications, and now scientists likely know why.

Phosphate Binder Use Has Declined Over the Past Two Years in the U.S. Dialysis Setting, While Sensipar Use in Hemodialysis has Declined Since Last Year

EXTON, Pa., June 5, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the use of phosphate binders in the U.S. has declined in both the hemodialysis and peritoneal dialysis setting over the past two years. (Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO ) The ChartTrends: B...

Dialysis: Heparin-free haemodialysis—use and outcomes

Shen et al. report that heparin-free haemodialysis is not associated with a decreased risk of death, bleeding, atherothrombosis and venous thromboembolism compared with standard haemodialysis using heparin. These data suggest that the assumption tha...

Dialysis: Small solute uraemic toxin generation and adequacy of dialysis

A new paper by Sridharan and colleagues compares the roles of energy metabolism, body composition and energy expenditure in determining uraemic toxin generation in patients on haemodialysis. The researchers conclude that these factors have an importa...

Solid Showing At WCN Conference For Keryx: Catalysts Still To Come

ByPropThink:By Jake KingKeryx Biopharmaceuticals (KERX) presented additional details from its pivotal Phase III study for Zerenex Monday at the World Congress of Nephrology (WVN) meeting during a lunch presentation. Some early profit taking this morning took the stock off of its pre-market highs, creating a buying opportunity on the positive results. The additional Phase III data for the phosphate...

End-Of-Life Care: A Challenge In Terms Of Costs And Quality

The Medicare NewsGroup takes a long look at the issues surrounding end-of-life care within the American health care system with a series of stories, including these: The Medicare NewsGroup: The Cost And Quality Conundrum Of American End-Of-Life Care At first glance, America is making great strides toward a medical and cultural shift in its approach to end-of-life care: More and more providers are...

Akebia Closes $41 Million Series C

--Proceeds to Support Phase 2b Trial and Phase 3 Preparations for Promising Anemia Drug Candidate-- Akebia Therapeutics, a biotech company focused on developing and commercializing small molecules to treat anemia and cancer, today announced that it has completed a $41 million Series C financing. The proceeds of this financing will be used to fund the o...

DialysisPPO Issued Patent for Health Plan Language Limiting Exposure to Costly Dialysis Claims

KING OF PRUSSIA, Pa., June 4, 2013 /PRNewswire/ -- DialysisPPO, founded in 2006 to help employer-group health plans ("EGHPs") manage the high cost of chronic, long-term dialysis - typically for the treatment of End-Stage Renal Disease ("ESRD") - announced today that the United States Patent and Trademark Office (USPTO) issued a patent covering our dialysis cost containment solution that limits exp...

Paladina Health Opens Its 35th Innovative Primary Care Clinic

Employer-sponsored medical home model delivers higher-quality, lower-cost health care to employers and individuals Paladina Health, LLC, an innovative employer-sponsored medical home health care provider, today announced the opening of the 35th clinic in its growing nationwide network. Located at 32275 32nd Ave. S. in Federal Way, Was...

NYC Rehab Center Consortium Centers for Specialty Care Group Sponsors Major Charity Events and Highlights Its 5-star Rating

NEW YORK, June 4, 2013 /PRNewswire/ -- Centers for Specialty Care Group, a care-giving consortium of nursing homes in New York and New Jersey, has proven its commitment to community development by sponsoring the Annual North Rockland Community 3-mile Run/Walk. Found online at http://www.CentersHealthcare.com, the group is dedicated to setting higher standards in care, as well as betterin...

People on dialysis likelier to get heart attack

Scientists in Japan have discovered why patients, who are suffering from advanced kidney disease, and undergoing hemodialysis are at high risk to heart attacks and other cardiovascular complications. (Times of India)